Нет,не снижает.Существенно снижает риски только раннее и довольно интенсивное воздействие на атеросклеротический процесс.
Эффективна,если соблюдены условия ее применения :
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy?view=fullDolutegravir plus Lamivudine or Emtricitabine
A switch from a stable three-drug ARV regimen to DTG plus 3TC or FTC as a maintenance strategy in patients with ongoing virologic suppression and no history of prior virologic failure or resistance to these agents was noninferior to continuing a three-drug therapy in a large randomized clinical trial (TANGO), in smaller clinical trials, and in observational studies(AI). Individuals with active Hepatitis B infection need to be on a specific HBV active regimen, because 3TC or FTC monotherapy is not considered standard of care for HBV therapy.
Это не единственная стратегия свитча,ещё есть.Например есть стратегия долутегравир+рилпивирин.
Dolutegravir plus Rilpivirine
Two Phase 3 trials, SWORD-1 and SWORD-2, demonstrated noninferior efficacy of DTG with RPV compared to continuing a first or second ARV regimen in individuals with suppressed HIV-RNA and without prior virologic failure, active Hepatitis B (unless the patient is also on a specific HBV active regimen), resistance to DTG or RPV, or significant drug interactions (AI).
Эту тему просматривают: 7 (пользователей: 0 , гостей: 7)